Dr Aakash Pandit speaks to ecancer about a large meta analysis of nine phase 3 trials evaluating PARP inhibitor maintenance therapy in first line ovarian cancer, focusing on how emerging evidence can better guide treatment decisions.

With over 6500 patients included, the study provides a comprehensive assessment of survival outcomes and safety across different molecular subgroups.

The findings confirm that PARP inhibitors significantly improve progression free and overall survival in the overall population, but importantly reveal a clear gradient of benefit based on biomarker status.

Patients with BRCA mutations derive the greatest benefit, followed by those with homologous recombination deficiency, while benefit is more modest in biomarker negative disease.

Dr Pandit also addresses the balance between efficacy and toxicity, as PARP inhibitors were associated with a substantially higher risk of serious adverse events. Experts highlight how these data support a shift toward a biomarker driven approach, tailoring treatment intensity to maximise benefit while minimising unnecessary toxicity.

Overall, the interview explores how these results may reshape clinical guidelines, moving away from a one size fits all strategy toward more personalised, evidence based use of PARP inhibitor maintenance in ovarian cancer.